Actively recruiting phase 2 trial of PVSRIPO for advanced, PD-1–refractory melanoma
PVSRIPO with or without anti-PD-1 therapy in advanced melanoma following PD-1 failure
The LUMINOS-102 trial is designed to build on the results of the phase 1 trial of PVSRIPO, in which clinical responses were observed in injected and noninjected tumors in patients with unresectable, treatment-refractory melanoma.
Overview of LUMINOS-102
Download the peer-reviewed publication in the Journal for ImmunoTherapy of Cancer with the results of the phase 1 PVSRIPO trial in unresectable, treatment-refractory melanoma
